{"transactions":[{"id":1084616,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:06:15.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":315000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the third tranche of the January 2024 Offering."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":315000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":315000},"source":{"system":"sec-edgar","filing":"0001193805-25-001068","document":"e664708_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001068/e664708_4-duane.xml","form_type":"4"}},{"id":1084615,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:06:15.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":315000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the second tranche of the Issuer's January 4, 2024 private placement (the \"January 2024 Offering\")."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":315000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":315000},"source":{"system":"sec-edgar","filing":"0001193805-25-001068","document":"e664708_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001068/e664708_4-duane.xml","form_type":"4"}},{"id":1084614,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:06:15.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":630000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series B purchase warrants by the holders thereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":630000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":630000},"source":{"system":"sec-edgar","filing":"0001193805-25-001068","document":"e664708_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001068/e664708_4-duane.xml","form_type":"4"}},{"id":1084613,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:06:15.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":630000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series A purchase warrants by the holders thereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":630000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":630000},"source":{"system":"sec-edgar","filing":"0001193805-25-001068","document":"e664708_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001068/e664708_4-duane.xml","form_type":"4"}},{"id":1084612,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:06:15.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":315000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":315000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":315000},"source":{"system":"sec-edgar","filing":"0001193805-25-001068","document":"e664708_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001068/e664708_4-duane.xml","form_type":"4"}},{"id":1104853,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2025-06-20T21:15:28.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":570000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":570000,"derivative":{"exercise_price":0.7729,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":570000},"source":{"system":"sec-edgar","filing":"0001193805-25-000922","document":"e664637_4a-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000922/e664637_4a-duane.xml","form_type":"4/A","original_submission_date":"2025-06-09"}},{"id":1109659,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-06-16T21:00:19.000Z","date":"2025-06-13","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":0.8347,"value":16694.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.83 to $0.84. The Reporting Person (RP) undertakes to provide to the Issuer, any securityholder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price."}],"balance_after":36032,"source":{"system":"sec-edgar","filing":"0001193805-25-000885","document":"e664632_4-duane.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000885/e664632_4-duane.xml","form_type":"4"}},{"id":1117688,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2025-06-09T20:06:06.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":560000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":560000,"derivative":{"exercise_price":0.7729,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":560000},"source":{"system":"sec-edgar","filing":"0001193805-25-000836","document":"e664604_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000836/e664604_4-duane.xml","form_type":"4"}},{"id":1338840,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-12-09T13:30:26.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":300000,"derivative":{"exercise_price":1.25,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001193805-24-001448","document":"e664066_4a-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524001448/e664066_4a-duane.xml","form_type":"4/A","original_submission_date":"2024-12-06"}},{"id":1340266,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-12-06T22:32:07.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months."}],"balance_after":300000,"derivative":{"exercise_price":1.25,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001193805-24-001444","document":"e664062_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524001444/e664062_4-duane.xml","form_type":"4"}},{"id":1591215,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-03-07T02:52:02.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":379959,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":379959,"derivative":{"exercise_price":1.72,"underlying":"Common Stock","underlying_shares":379959},"source":{"system":"sec-edgar","filing":"0001193805-24-000324","document":"e619338_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000324/e619338_4-duane.xml","form_type":"4"}},{"id":1591214,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-03-07T02:52:02.000Z","date":"2024-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":0,"derivative":{"exercise_price":3.4,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193805-24-000324","document":"e619338_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000324/e619338_4-duane.xml","form_type":"4"}},{"id":1591213,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-03-07T02:52:02.000Z","date":"2024-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":0,"derivative":{"exercise_price":10.88,"expiration_date":"2032-03-10","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001193805-24-000324","document":"e619338_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000324/e619338_4-duane.xml","form_type":"4"}},{"id":1591212,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-03-07T02:52:02.000Z","date":"2024-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":0,"derivative":{"exercise_price":14.77,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193805-24-000324","document":"e619338_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000324/e619338_4-duane.xml","form_type":"4"}},{"id":1591211,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-03-07T02:52:02.000Z","date":"2024-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":0,"derivative":{"exercise_price":15.44,"expiration_date":"2031-04-15","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001193805-24-000324","document":"e619338_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000324/e619338_4-duane.xml","form_type":"4"}},{"id":1591210,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-03-07T02:52:02.000Z","date":"2024-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":120000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2030-10-22","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001193805-24-000324","document":"e619338_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000324/e619338_4-duane.xml","form_type":"4"}},{"id":1591209,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-03-07T02:52:02.000Z","date":"2024-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":0,"derivative":{"exercise_price":12.3,"expiration_date":"2030-07-02","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001193805-24-000324","document":"e619338_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000324/e619338_4-duane.xml","form_type":"4"}},{"id":1591208,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-03-07T02:52:02.000Z","date":"2024-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":0,"derivative":{"exercise_price":12.3,"expiration_date":"2030-07-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193805-24-000324","document":"e619338_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000324/e619338_4-duane.xml","form_type":"4"}},{"id":1591207,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-03-07T02:52:02.000Z","date":"2024-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19973,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":0,"derivative":{"exercise_price":13.63,"expiration_date":"2029-07-22","underlying":"Common Stock","underlying_shares":19973},"source":{"system":"sec-edgar","filing":"0001193805-24-000324","document":"e619338_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000324/e619338_4-duane.xml","form_type":"4"}},{"id":1591206,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-03-07T02:52:02.000Z","date":"2024-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9986,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":0,"derivative":{"exercise_price":13.63,"expiration_date":"2029-07-22","underlying":"Common Stock","underlying_shares":9986},"source":{"system":"sec-edgar","filing":"0001193805-24-000324","document":"e619338_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000324/e619338_4-duane.xml","form_type":"4"}},{"id":1675093,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-01-19T21:07:16.000Z","date":"2024-01-17","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":300000,"derivative":{"exercise_price":1.21,"expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001193805-24-000069","document":"e619199_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000069/e619199_4-duane.xml","form_type":"4"}},{"id":2060205,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2023-01-07T02:31:18.000Z","date":"2023-01-02","kind":"grant","acquired":true,"shares":132000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":132000,"derivative":{"exercise_price":1.4,"expiration_date":"2033-01-01","underlying":"Common Stock","underlying_shares":132000},"source":{"system":"sec-edgar","filing":"0001193805-23-000022","document":"e618184_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380523000022/e618184_4-duane.xml","form_type":"4"}},{"id":2227388,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2022-06-18T01:35:34.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months."}],"balance_after":10000,"derivative":{"exercise_price":3.4,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193805-22-000974","document":"e621761_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380522000974/e621761_4-duane.xml","form_type":"4"}},{"id":2271788,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-05-13T12:31:11.000Z","date":"2022-05-12","kind":"gift","acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents a gift of 6,000 shares."}],"balance_after":16032,"source":{"system":"sec-edgar","filing":"0001193805-22-000787","document":"e621652_4-duane.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380522000787/e621652_4-duane.xml","form_type":"4"}},{"id":2271787,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-05-13T12:31:11.000Z","date":"2022-05-12","kind":"purchase","acquired":true,"shares":10000,"price":5.03,"value":50300.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a purchase of 10,000 shares."}],"balance_after":22032,"source":{"system":"sec-edgar","filing":"0001193805-22-000787","document":"e621652_4-duane.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380522000787/e621652_4-duane.xml","form_type":"4"}},{"id":2337374,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2022-03-11T22:02:21.000Z","date":"2022-03-10","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":75000,"derivative":{"exercise_price":10.88,"expiration_date":"2032-03-10","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001193805-22-000473","document":"e621442_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380522000473/e621442_4-duane.xml","form_type":"4"}},{"id":2454024,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-01-03T13:00:43.000Z","date":"2021-11-08","kind":"gift","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a gift of stock."}],"balance_after":12032,"source":{"system":"sec-edgar","filing":"0001193805-22-000002","document":"e621189_5-duane.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380522000002/e621189_5-duane.xml","form_type":"5"}},{"id":2606712,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2021-08-11T13:02:52.000Z","date":"2021-08-10","kind":"purchase","acquired":true,"shares":1000,"price":9.8,"value":9800.0,"ownership":{"direct":true},"balance_after":15032,"source":{"system":"sec-edgar","filing":"0001193805-21-001159","document":"e620865_4-duane.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380521001159/e620865_4-duane.xml","form_type":"4"}},{"id":2669942,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2021-06-14T23:13:02.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":10000,"derivative":{"exercise_price":14.77,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193805-21-000874","document":"e620712_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380521000874/e620712_4-duane.xml","form_type":"4"}},{"id":2716131,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2021-05-12T20:31:27.000Z","date":"2021-05-12","kind":"purchase","acquired":true,"shares":4000,"price":12.75,"value":51000.0,"ownership":{"direct":true},"balance_after":14032,"source":{"system":"sec-edgar","filing":"0001193805-21-000654","document":"e620591_4-duane.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380521000654/e620591_4-duane.xml","form_type":"4"}},{"id":2744933,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2021-04-19T20:30:22.000Z","date":"2021-04-15","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in twelve monthly installments beginning on May 15, 2021."}],"balance_after":90000,"derivative":{"exercise_price":15.44,"expiration_date":"2031-04-15","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001193805-21-000512","document":"e620490_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380521000512/e620490_4-duane.xml","form_type":"4"}},{"id":3001396,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2020-10-22T23:40:50.000Z","date":"2020-10-22","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in six monthly installments beginning on November 15, 2020."}],"balance_after":120000,"derivative":{"exercise_price":17,"expiration_date":"2030-10-22","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001193805-20-001306","document":"e620014_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380520001306/e620014_4-duane.xml","form_type":"4"}},{"id":3088557,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-07-07T00:18:49.000Z","date":"2020-07-02","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":45000,"derivative":{"exercise_price":12.3,"expiration_date":"2030-07-01","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001193805-20-000800","document":"e619753_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380520000800/e619753_4-duane.xml","form_type":"4"}},{"id":3352343,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-12-05T00:00:27.000Z","date":"2019-12-02","kind":"exercise","acquired":false,"shares":22157,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On January 11, 2019, the Reporting Person was granted 886,316 restricted stock units as consideration of cancelled stock options. Pursuant to the Reporting Person's amended RSU Agreement, RSUs that vested prior to April 22, 2019 were settled on December 2, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On January 11, 2019, the Reporting Person was granted 886,316 restricted stock units as consideration of cancelled stock options. Pursuant to the Reporting Person's amended RSU Agreement, RSUs that vested prior to April 22, 2019 were settled on December 2, 2019."}],"balance_after":864159,"derivative":{"underlying":"Common Stock","underlying_shares":22157},"source":{"system":"sec-edgar","filing":"0001193805-19-001904","document":"e619223_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380519001904/e619223_4-duane.xml","form_type":"4"}},{"id":3352342,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-05T00:00:27.000Z","date":"2019-12-04","kind":"sale","acquired":false,"shares":4400,"price":6.96,"value":30624.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":10032,"source":{"system":"sec-edgar","filing":"0001193805-19-001904","document":"e619223_4-duane.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380519001904/e619223_4-duane.xml","form_type":"4"}},{"id":3352341,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-05T00:00:27.000Z","date":"2019-12-03","kind":"tax_withholding","acquired":false,"shares":7930,"price":7.1541,"value":56732.013,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of RSUs granted to the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $7.1508 and $7.1572 per share."}],"balance_after":14432,"source":{"system":"sec-edgar","filing":"0001193805-19-001904","document":"e619223_4-duane.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380519001904/e619223_4-duane.xml","form_type":"4"}},{"id":3352340,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-05T00:00:27.000Z","date":"2019-12-02","kind":"exercise","acquired":true,"shares":22157,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."}],"balance_after":22362,"source":{"system":"sec-edgar","filing":"0001193805-19-001904","document":"e619223_4-duane.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380519001904/e619223_4-duane.xml","form_type":"4"}},{"id":3456609,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2019-07-24T21:46:42.000Z","date":"2019-07-22","kind":"grant","acquired":true,"shares":29959,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"9,986 of the options vest in monthly increments over a period of one year from the grant date, and 19,973 of the options vest in monthly increments over a period of three years from the grant date."}],"balance_after":29959,"derivative":{"exercise_price":13.63,"expiration_date":"2029-07-22","underlying":"Common Stock","underlying_shares":29959},"source":{"system":"sec-edgar","filing":"0001193805-19-000670","document":"e618564_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380519000670/e618564_4-duane.xml","form_type":"4"}},{"id":3696287,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Restricted Stock Units","published_at":"2019-01-15T02:47:38.000Z","date":"2019-01-11","kind":"grant","acquired":true,"shares":886316,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Vital Therapies, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), twenty five percent (25%) of the RSUs vest annually after the vesting commencement date of January 11, 2019. One hundred percent (100%) of the unvested portion of the RSUs, if any, shall vest in the event of a Termination without Cause or Resignation for Good Reason (each as defined in the reporting person's Change of Control and Severance Agreement)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), twenty five percent (25%) of the RSUs vest annually after the vesting commencement date of January 11, 2019. One hundred percent (100%) of the unvested portion of the RSUs, if any, shall vest in the event of a Termination without Cause or Resignation for Good Reason (each as defined in the reporting person's Change of Control and Severance Agreement)."}],"balance_after":886316,"derivative":{"underlying":"Common Stock","underlying_shares":886316},"source":{"system":"sec-edgar","filing":"0001280776-19-000014","document":"wf-form4_154752044124186.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000128077619000014/wf-form4_154752044124186.xml","form_type":"4"}},{"id":3696286,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2019-01-15T02:47:38.000Z","date":"2019-01-11","kind":"disposition_to_issuer","acquired":false,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the \"Plan\")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of June 9, 2018, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan)."}],"balance_after":0,"derivative":{"exercise_price":5,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001280776-19-000014","document":"wf-form4_154752044124186.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000128077619000014/wf-form4_154752044124186.xml","form_type":"4"}},{"id":3696285,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2019-01-15T02:47:38.000Z","date":"2019-01-11","kind":"disposition_to_issuer","acquired":false,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the \"Plan\")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of June 10, 2017, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan)."}],"balance_after":0,"derivative":{"exercise_price":3.2,"expiration_date":"2027-06-09","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001280776-19-000014","document":"wf-form4_154752044124186.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000128077619000014/wf-form4_154752044124186.xml","form_type":"4"}},{"id":3696284,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2019-01-15T02:47:38.000Z","date":"2019-01-11","kind":"disposition_to_issuer","acquired":false,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the \"Plan\")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of April 16, 2016, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan)."}],"balance_after":0,"derivative":{"exercise_price":8.28,"expiration_date":"2026-05-12","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001280776-19-000014","document":"wf-form4_154752044124186.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000128077619000014/wf-form4_154752044124186.xml","form_type":"4"}},{"id":3696283,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2019-01-15T02:47:38.000Z","date":"2019-01-11","kind":"disposition_to_issuer","acquired":false,"shares":241670,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation."}],"balance_after":0,"derivative":{"exercise_price":8,"exercise_date":"2016-09-13","expiration_date":"2022-09-25","underlying":"Common Stock","underlying_shares":241670},"source":{"system":"sec-edgar","filing":"0001280776-19-000014","document":"wf-form4_154752044124186.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000128077619000014/wf-form4_154752044124186.xml","form_type":"4"}},{"id":3696282,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2019-01-15T02:47:38.000Z","date":"2019-01-11","kind":"disposition_to_issuer","acquired":false,"shares":23344,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation."}],"balance_after":0,"derivative":{"exercise_price":0.4284,"exercise_date":"2016-04-25","expiration_date":"2022-04-24","underlying":"Common Stock","underlying_shares":23344},"source":{"system":"sec-edgar","filing":"0001280776-19-000014","document":"wf-form4_154752044124186.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000128077619000014/wf-form4_154752044124186.xml","form_type":"4"}},{"id":3696281,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2019-01-15T02:47:38.000Z","date":"2019-01-11","kind":"disposition_to_issuer","acquired":false,"shares":93377,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation."}],"balance_after":0,"derivative":{"exercise_price":0.4284,"exercise_date":"2016-02-08","expiration_date":"2022-03-31","underlying":"Common Stock","underlying_shares":93377},"source":{"system":"sec-edgar","filing":"0001280776-19-000014","document":"wf-form4_154752044124186.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000128077619000014/wf-form4_154752044124186.xml","form_type":"4"}},{"id":3892129,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2018-06-15T12:16:56.000Z","date":"2018-06-14","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an option to purchase shares of Akebia Therapeutics, Inc.'s (the \"Company's\") common stock granted by the Company pursuant to the Company's 2014 Incentive Plan (the \"Stock Option\").  100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company."}],"balance_after":12500,"derivative":{"exercise_price":11.14,"exercise_date":"2019-06-14","expiration_date":"2028-06-14","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001562180-18-003017","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218018003017/primarydocument.xml","form_type":"4"}},{"id":3898231,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2018-06-11T23:24:05.000Z","date":"2018-06-09","kind":"grant","acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly beginning on July 9, 2018, such that all of the shares of common stock subject to the option are vested by June 9, 2022, subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the \"Plan\")) through each vesting date; provided, that, 100% of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan)."}],"balance_after":85000,"derivative":{"exercise_price":5,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001280776-18-000073","document":"wf-form4_152875942911815.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000128077618000073/wf-form4_152875942911815.xml","form_type":"4"}},{"id":4051283,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-16T21:07:34.000Z","date":"2018-02-15","kind":"sale","acquired":false,"shares":1000,"price":14.62,"value":14620.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017."}],"balance_after":21499,"source":{"system":"sec-edgar","filing":"0001562180-18-001042","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218018001042/primarydocument.xml","form_type":"4"}},{"id":4191761,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-04T20:21:10.000Z","date":"2017-10-02","kind":"sale","acquired":false,"shares":1188,"price":19.64,"value":23332.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2017."}],"balance_after":22499,"source":{"system":"sec-edgar","filing":"0001562180-17-003207","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218017003207/primarydocument.xml","form_type":"4"}},{"id":4261482,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-07-06T16:23:51.000Z","date":"2017-07-03","kind":"sale","acquired":false,"shares":990,"price":14.27,"value":14127.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold by reporting person pursuant to a 10b5-1 plan to pay taxes in connection with the vesting of restricted stock pursuant to the December 23, 2013 award."}],"balance_after":23687,"source":{"system":"sec-edgar","filing":"0001562180-17-002433","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218017002433/primarydocument.xml","form_type":"4"}},{"id":4277089,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2017-06-19T20:04:53.000Z","date":"2017-06-15","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"100% of the option shares vest on the first anniversary of the date of grant (the \"Vesting Date\"), provided that the Reporting Person remains in continuous service as a member of the Issuer's Board of Directors through the Vesting Date, and provided further that the options held by the Reporting Person shall be eligible for vesting acceleration upon a \"Change in Control\" as defined and provided for in the Issuer's Non-Employee Director Stock Option Award Agreement."}],"balance_after":12500,"derivative":{"exercise_price":14.37,"exercise_date":"2018-06-15","expiration_date":"2027-06-15","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001562180-17-002292","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218017002292/primarydocument.xml","form_type":"4"}},{"id":4283450,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2017-06-14T00:12:12.000Z","date":"2017-06-10","kind":"grant","acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly beginning on July 10, 2017, such that all of the shares of common stock subject to the option are vested by June 10, 2021, subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the \"Plan\")) through each vesting date; provided, that, 100% of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan)."}],"balance_after":85000,"derivative":{"exercise_price":3.2,"expiration_date":"2027-06-09","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001280776-17-000067","document":"wf-form4_149739911768796.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000128077617000067/wf-form4_149739911768796.xml","form_type":"4"}},{"id":4286862,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2017-06-09T20:06:47.000Z","date":"2017-06-08","kind":"purchase","acquired":true,"shares":3900,"price":3.1236,"value":12182.04,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.10 to $3.15.  The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (1) to this Form 4."}],"balance_after":8224,"source":{"system":"sec-edgar","filing":"0001280776-17-000059","document":"wf-form4_149703879137117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000128077617000059/wf-form4_149703879137117.xml","form_type":"4"}},{"id":4359988,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-04-04T20:01:26.000Z","date":"2017-04-03","kind":"sale","acquired":false,"shares":991,"price":9.2021,"value":9119.2811,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold by reporting person pursuant to a 10b5-1 plan to pay taxes in connection with the vesting of restricted stock pursuant to a December 23, 2013 award."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price.  This transaction was executed in multiple trades at prices ranging from $9.19 to $9.21, inclusive.  The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":24677,"source":{"system":"sec-edgar","filing":"0001562180-17-001430","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218017001430/primarydocument.xml","form_type":"4"}},{"id":4489772,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2017-01-17T21:01:59.000Z","date":"2016-12-23","kind":"gift","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares gifted by reporting person for no consideration."}],"balance_after":4324,"source":{"system":"sec-edgar","filing":"0001280776-17-000003","document":"wf-form5_148468690602702.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000128077617000003/wf-form5_148468690602702.xml","form_type":"5"}},{"id":4507258,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-01-03T21:02:15.000Z","date":"2017-01-03","kind":"sale","acquired":false,"shares":1980,"price":10.4601,"value":20710.998,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"47,525 shares of restricted stock (as adjusted from 27,157 shares prior to the 1.75-for-1 stock split effected on March 6, 2014) were awarded on December 23, 2013. Fifty percent of the shares vested on December 23, 2014. The remaining fifty percent vest ratably on the first day of each calendar quarter over three years from the first anniversary of the grant date until fully vested, assuming continued service through the applicable vesting date."},{"field":"shares","element":"transactionShares","label":"F2","text":"Shares sold by reporting person pursuant to a 10b5-1 plan in connection with the vesting of restricted stock pursuant to the December 23, 2013 award described in footnote 1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.42 to $10.58, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":25668,"source":{"system":"sec-edgar","filing":"0001562180-17-000081","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218017000081/primarydocument.xml","form_type":"4"}},{"id":4586006,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-04T20:12:30.000Z","date":"2016-10-03","kind":"sale","acquired":false,"shares":1981,"price":8.9581,"value":17745.9961,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"47,525 shares of restricted stock (as adjusted from 27,157 shares prior to the 1.75-for-1 stock split effected on March 6, 2014) were awarded on December 23, 2013. Fifty percent of the shares vested on December 23, 2014. The remaining fifty percent vest ratably on the first day of each calendar quarter over three years from the first anniversary of the grant date until fully vested, assuming continued service through the applicable vesting date."},{"field":"shares","element":"transactionShares","label":"F2","text":"Shares sold by reporting person pursuant to a 10b5-1 plan to pay taxes in connection with the vesting of restricted stock pursuant to the December 23, 2013 award described in footnote 1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.88 to $9.00, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":27648,"source":{"system":"sec-edgar","filing":"0001562180-16-003208","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218016003208/primarydocument.xml","form_type":"4"}}]}